This afternoon we watched Zoetis rise 1.6% to a price of $178.59 per share. The large-cap Pharmaceutical company is now trading -16.9% below its average target price of $214.92. Analysts have set target prices ranging from $180.0 to $260.0 per share for Zoetis, and have given the stock an average rating of buy.
The stock has a very low short interest at 1.1%, and a short ratio of 2.69. The company's insiders own 0.2% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 94.4% of Zoetis's shares being owned by this investor type.
Institutions Invested in Zoetis
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2022-12-31 | Blackrock Inc. | 9% | 40,083,985 | $7,158,598,734 |
| 2022-12-31 | Vanguard Group, Inc. (The) | 8% | 36,850,763 | $6,581,177,629 |
| 2022-12-31 | State Street Corporation | 4% | 19,868,824 | $3,548,373,205 |
| 2022-12-31 | AllianceBernstein, L.P. | 4% | 19,510,212 | $3,484,328,689 |
| 2022-12-31 | State Farm Mutual Automobile Insurance Co | 4% | 17,134,819 | $3,060,107,262 |
| 2022-12-31 | Bank of America Corporation | 3% | 14,146,596 | $2,526,440,527 |
| 2022-12-31 | Capital International Investors | 3% | 12,651,002 | $2,259,342,400 |
| 2022-12-31 | Wellington Management Group, LLP | 3% | 11,616,674 | $2,074,621,767 |
| 2022-12-31 | Morgan Stanley | 2% | 10,872,704 | $1,941,756,167 |
| 2022-12-31 | Geode Capital Management, LLC | 2% | 9,712,273 | $1,734,514,799 |
